Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.

ABSTRACT:

Background

The effect of alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, on coronary plaque burden in patients with familial hypercholesterolemia has not been addressed. Our aim was to assess changes in coronary plaque burden and its characteristics after treatment with alirocumab by quantification and characterization of atherosclerotic plaque throughout the coronary tree on the basis of a noninvasive analysis of coronary computed tomographic angiography in asymptomatic subjects with familial hypercholesterolemia receiving optimized and stable treatment with maximum tolerated statin dose with or without ezetimibe.

Methods

This study is a phase IV, open-label, multicenter, single-arm clinical trial to assess changes in coronary plaque burden an

SUBMITTER: Perez de Isla L 

PROVIDER: S-EPMC10158600 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature